25 February
2025
PureTech Health plc
PureTech to Present at the Leerink Partners
Global Healthcare Conference
PureTech Health
plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to changing the
lives of patients with devastating diseases, today announced that
Bharatt Chowrira, PhD, JD, Chief Executive
Officer, and Eric Elenko, PhD, Co-founder and President, will
participate in a fireside chat at the Leerink Partners Global
Healthcare Conference on Tuesday, March 11, 2025, at 1:00pm
EDT. A webcast of the presentation will be available at
https://investors.puretechhealth.com.
About PureTech
Health
PureTech is a clinical-stage biotherapeutics company
dedicated to giving life to new classes of medicine to change the
lives of patients with devastating diseases. The Company has
created a broad and deep pipeline through its experienced research
and development team and its extensive network of scientists,
clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D
engine has resulted in the development of 29 therapeutics and
therapeutic candidates, including three that have been approved by
the U.S. Food and Drug Administration. A number of these programs
are being advanced by PureTech or its Founded Entities in various
indications and stages of clinical development, including
registration-enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates
were initially identified or discovered and then advanced by
the PureTech team through key validation points.
For more information, visit www.puretechhealth.com or
connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains statements that are or may
be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those related to our upcoming presentation at
the Leerink Partners Global Healthcare Conference and our future
prospects, developments and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not
limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2023, filed with the SEC
and in our other regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
UK/EU
Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US
Media
Justin Chen
+1-609-578-7230
jchen@tenbridgecommunications.com
